• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Kamada Ltd.

    3/11/26 7:00:07 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email
    6-K 1 ea0280560-6k_kamada.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    For the Month of March 2026

     

    Commission File Number 001-35948

     

    Kamada Ltd.

    (Translation of registrant’s name into English)

     

    2 Holzman Street
    Science Park, P.O. Box 4081
    Rehovot 7670402
    Israel
    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

    This Form 6-K is being incorporated by reference into the Registrant’s Form S-8 Registration Statements, File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267 and 333-265866.

     

    The following exhibits are attached:

     

    99.1   Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
    99.2   Kamada Reports Record Top and Bottom-Line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
    99.3   Investors Deck

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 11, 2026 KAMADA LTD.
       
      By: /s/ Nir Livneh
       

    Nir Livneh

    Vice President General Counsel and
    Corporate Secretary

     

    2

     

     

    EXHIBIT INDEX

     

    EXHIBIT NO.   DESCRIPTION
    99.1   Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy
    99.2   Kamada Reports Record Top and Bottom-Line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth
    99.3   Investors Deck

     

    3

     

    Get the next $KMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Kamada with a new price target

    The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

    3/21/25 8:11:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Kamada with a new price target

    Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

    7/3/24 7:31:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    SEC Filings

    View All

    SEC Form 20-F filed by Kamada Ltd.

    20-F - KAMADA LTD (0001567529) (Filer)

    3/11/26 7:24:34 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    3/11/26 7:00:07 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    3/4/26 7:00:13 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

    2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-YearCompany Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic GrowthGenerated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of Available Cash Company Aims to Secure New Business Development and M&A Transactions to Accelerate Profitable GrowthCompany Adopted an Annual Cash Dividend Policy and Declares Cash Dividend of $0.25 Per Share (Totaling Approximately $14.4 Million)Conference

    3/11/26 7:02:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

    REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Company's ordinary shares (totaling approximately $14.4 million). The cash dividend will be payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026. The dividend payment is made in accordance with the Company's annual cash dividend policy newly adopted b

    3/11/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

    REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026. Kamada's management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may part

    3/4/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Financials

    Live finance-specific insights

    View All

    Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

    2025 Full Year Revenue of $180.5 Million, up 12% Year-over-Year; Adjusted EBITDA of $42.0 Million, up 23% Year-over-Year; Net Income of $20.2 Million, up 40% Year-over-YearCompany Affirms 2026 Annual Guidance of $200 Million – $205 Million in Revenues and $50 Million – $53 Million of Adjusted EBITDA, Representing Double-Digit Organic GrowthGenerated $25.5 Million of Cash from Operations in 2025; as of December 31, 2025 had $75.5 Million of Available Cash Company Aims to Secure New Business Development and M&A Transactions to Accelerate Profitable GrowthCompany Adopted an Annual Cash Dividend Policy and Declares Cash Dividend of $0.25 Per Share (Totaling Approximately $14.4 Million)Conference

    3/11/26 7:02:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Declares Cash Dividend of $0.25 Per Share, to be Paid in Accordance with an Adopted Annual Cash Dividend Policy

    REHOVOT, Israel and HOBOKEN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a cash dividend of $0.25 (approximately NIS 0.77) per share on the Company's ordinary shares (totaling approximately $14.4 million). The cash dividend will be payable on April 6, 2026, to shareholders of record at the close of business on March 23, 2026. The dividend payment is made in accordance with the Company's annual cash dividend policy newly adopted b

    3/11/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Fiscal Year and Fourth Quarter 2025 Financial Results on March 11, 2026

    REHOVOT, Israel, and HOBOKEN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the fourth quarter and fiscal year that ended December 31, 2025, prior to the open of the U.S. financial markets on Wednesday, March 11, 2026. Kamada's management will host an investment community conference call on Wednesday, March 11, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may part

    3/4/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

    8/30/23 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

    5/24/23 7:05:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/12/24 12:41:57 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care